Dry Age-Related Macular Degeneration Market
The dry age-related macular degeneration AMD
market research is expected
to cross USD 17.92 Billion by 2032 at a CAGR of 8.2% during the forecast
period. This degenerative eye disease is caused by the thinning of the
macula and interferes with a clear vision in the elderly. The macula is part of
the retina that facilitates clear vision; when this part of the eye
deteriorates, it causes blurred or distorted vision. But this does not mean
that the individual will lose his or her sight, only the central vision is
affected by this degenerative disease, and the peripheral vision remains
intact. Vision loss is slow and can be corrected using innovative ocular
treatments. It has been estimated that
the Dry Age-Related Macular
Degeneration Market has seen a jump due to increased research in drugs,
rising amount of COVID-19 cases among the old and age-restricted chronic
diseases.
List of Dry Age-Related Macular Degeneration Market Players Covered
in this report:
Santen Pharmaceuticals Inc. (Japan),
Allergan plc (Ireland),
Bausch Health (Canada),
Alimera Science Inc. (US),
Phio Pharmaceuticals Corp (US),
Ocumension Therapeutics Co. Ltd (China),
Belite Bio Inc. (US),
Kubota Vision Inc. (US),
Iveric Bio (US),
Eyestem Research Pvt Ltd (India),
Yuyang DNU Co., Ltd (South Korea),
Stealth Biotherapeutics Inc. (US)
Segment Analysis
The global Dry Age-Related Macular Degeneration Market
Insights has been divided based on stages, age group, route of administration,
diagnosis& treatment, and end user.
The market, based on
stages, has been segregated into early age-related macular degeneration,
intermediate age-related macular degeneration, and late age-related macular
degeneration.
Based on age group,
the dry AMD market has been divided into above 75 years, above 60 years, and
above 40 years.
Based on diagnosis
& treatment, the dry AMD market has been divided into treatment and
diagnosis.
Treatment type is further bifurcated into nutrition therapy
and telescopic lens implant. Nutrition therapy is again divided into
antioxidants and others. Antioxidants areal so segregated as vitamins, zinc,
copper, omega-3 fatty acids, and others.
Diagnosis is bifurcated into fluorescein angiogram,
preliminary test, optical coherence tomography, and others.
Based on route of
administration, the market is bifurcated into oral, intravitreal, and
others.
On the basis of end
user, the market is bifurcated into hospitals and clinics, diagnostic
centers, academic research institutes, and others
Dry Age-Related Macular Degeneration Market Share
It has been reported by the American Academy of
Ophthalmology that about 11 million people over the age of fifty experience
blindness as a result of AMD. Hence making it a supple market for AMD related
treatments. Obesity-related macular degeneration is also on the rise in North
America, along with high blood pressure from an erratic lifestyle.
Advances in research and development in Europe and
Asia-Pacific have enabled more patients to see more clearly. The African
continent, particularly the Sahara subcontinent, has experienced a significant
increase in dry age-related macular degeneration due to lack of vitamin A and
poor dietary standards. Thus making this region the key player for
pharmaceutical companies to invest in.
The key companies that are invested into creating feasible
solutions for AMD are Pfizer, Bayer AG, Regenron Pharmaceutical Inc.,
GlaxoSmithKline plc, and Novartis AG.
Dry Age-Related Macular Degeneration Market Growth
The Dry
Age-Related Macular Degeneration Market Trends is led by dry and wet drug
solutions that treat this degenerative disease. Wet age-related AMD will soon
see a jump of 95% in the year 2022. After the impact of COVID-19, it has been
observed that wet macular degeneration has affected most of the ageing
population. In this type, there is an atypical growth of blood vessels beneath
the retina, causing it to bleed create vision obstruction. Developed countries
have introduced intraocular anti-VEGF injections for patients suffering from
wet AMD, thus increasing treatment capacity globally.
In recent years, Stargardt
disease, a genetically inherited retinal disorder that has become dominant
among the younger population, has given impetus for research towards macular
degeneration drugs.
Lucentis, Avastin, Eylea and Visudyne are some of the
prominent drugs available in the market to treat dry age-related macular
degeneration. The Lucentis market has grown rapidly in developed countries
since the government introduced healthcare benefits for the elderly through
affordable treatments.
Dry Age-Related Macular Degeneration Market Value
It has been noted that off-label drugs are getting more
popular due to their affordability than on-label drugs to treat AMD. An
off-label drug like Avastin is sold rapidly in the market for patients who can
get treated within their income budget.
On a case-by-case basis, the market is segmented into
intravenous and intravitreous. It is said that the intravitreal segment
dominates the market because it is most effective because of the targeted
distribution of drugs. Furthermore, the majority of anti-VEGF injections are
given intravitreally or intraocular.
Industry News
Recent data released by the World Bank statistics indicate
that the older generation living above 65% is rising. They represent
approximately 8.873% of the population, indicating that patients with AMD will
increase due to chronic diseases and diseases.
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
No comments:
Post a Comment